Evidence map›Paper›PMID 21917892›Full record

Trial reportThe Journal of infectious diseases2011

Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results.

Paul E Sax, Camlin Tierney, Ann C Collier, Eric S Daar, Katie Mollan, Chakra Budhathoki, Catherine Godfrey, Nasreen C Jahed, Laurie Myers, David Katzenstein and 9 more

Open access · greenAbstract readClinical TrialComparative StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The Journal of infectious diseases, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 78 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
78citing papers in PubMed, 7 pooled it
14.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

78 citing papers in PubMed, 7 syntheses or guidelines pooled it, 176 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Guideline
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Impact of Medication Adherence on Virologic Failure in A5202: A Randomized, Partially Blinded, Phase 3B Study.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2017
    Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Outcomes by sex following treatment initiation with atazanavir plus ritonavir or efavirenz with abacavir/lamivudine or tenofovir/emtricitabine.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2014
    Trial

18 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors at 16 institutions in 4 countries.

Paul E SaxDivision of Infectious Diseases, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA. psax@partners.org
Camlin Tierney
Ann C Collier
Eric S Daar
Katie Mollan
Chakra Budhathoki
Catherine Godfrey
Nasreen C Jahed
Laurie Myers
David Katzenstein
Awny Farajallah
James F Rooney
Belinda Ha
William C Woodward
Judith Feinberg
Karen Tashima
Robert L Murphy
Margaret A Fischl
AIDS Clinical Trials Group Study A5202 Team
Harvard University · USAbbott (United Kingdom) · GBBrigham and Women's Hospital · USBristol-Myers Squibb (United States) · USBrown University · USFrontier Science & Technology Research Foundation · USGilead Sciences (United States) · USHarborview Medical Center · USNational Institute of Allergy and Infectious Diseases · USNorthwestern University · USResearch Triangle Park Foundation · USSocial and Scientific Systems (United States) · USStanford University · USThe Lundquist Institute · USUniversity of Cincinnati · USUniversity of Miami · US

Funding

Statistical and Data Management Center (SDMC), AIDS Clinical Trials Group (ACTG)UM1AI068634 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Marlene Ann Cooper, Michael David Hughes · 2011 to 2026
$246.6M
WOMEN'S HEALTH AGENDAU01AI038858 · NIAID · SOCIAL AND SCIENTIFIC SYSTEMS, INC. · PI BENSON, CONSTANCE ANN · 1996 to 2008
$157.5M
AIDS Clinical Trials Group NetworkU01AI068636 · NIAID · SOCIAL AND SCIENTIFIC SYSTEMS, INC. · PI KURITZKES, DANIEL R. · 2006 to 2010
$147.1M
Virus & Reservoirs CoreP30AI045008 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI DAVID S METZGER · 1999 to 2026
$78.6M
Virology, Immunology, and Microbiology CoreP30AI050410 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2001 to 2026
$76.9M
ZONA-FREE HAMSTER OVA ASSAY AS AN INDICATOR OF MALE FERTILITYM01RR000425 · NCRR · LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER · PI WANG, CHRISTINA C. · 1985 to 2011
$74.2M
Virology and Molecular Biomarkers CoreP30AI050409 · NIAID · EMORY UNIVERSITY · PI Hannah LF Cooper · 2002 to 2026
$74.0M
Statistical and Data Management Center for the AIDS Clinical Trials GroupU01AI068634 · NIAID · HARVARD SCHOOL OF PUBLIC HEALTH · PI HUGHES, MICHAEL DAVID · 2006 to 2010
$71.9M
University of North Carolina Global HIV Prevention and Treatment Clinical Trials Unit 2024 SupplementUM1AI069423 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Joseph J Eron, MINA CHRISTINE HOSSEINIPOUR · 2012 to 2026
$71.8M
CTSA INFRASTRUCTURE FOR PEDIATRIC RESEARCHUL1RR025780 · NCRR · UNIVERSITY OF COLORADO DENVER · PI SOKOL, RONALD J. · 2008 to 2011
$61.3M
UCLA Clinical and Translational Science InstituteUL1TR000124 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DUBINETT, STEVEN M. · 2012 to 2015
$57.0M
CTSA INFRASTRUCTURE FOR PEDIATRIC RESEARCHUL1RR024156 · NCRR · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI GINSBERG, HENRY N · 2006 to 2011
$53.0M
NCATS NIH HHS UL1 TR000124NCATS NIH HHS UL1 TR000454NCRR NIH HHS 1UL1 RR024156NCRR NIH HHS 1UL1 RR025777-01NCRR NIH HHS M01 RR000046NCRR NIH HHS M01 RR000425NCRR NIH HHS M01-RR00425NCRR NIH HHS RR00046NCRR NIH HHS RR024996NCRR NIH HHS RR025747NCRR NIH HHS RR025780NCRR NIH HHS U54 RR023561NCRR NIH HHS UL1 RR024156NCRR NIH HHS UL1 RR024160NCRR NIH HHS UL1 RR024996NCRR NIH HHS UL1 RR025747NCRR NIH HHS UL1 RR025777NCRR NIH HHS UL1 RR025780NCRR NIH HHS UL1 RR033176NIAID NIH HHS 1U01 AI069472-01NIAID NIH HHS 1U01 AI069494-01NIAID NIH HHS 1U01 AI069502-01NIAID NIH HHS 1U01 AI69467-01NIAID NIH HHS 3U01 AI046376 05S4NIAID NIH HHS 5P30 AI045008-10NIAID NIH HHS 5U01 AI069415-03NIAID NIH HHS 5U01 AI069418NIAID NIH HHS 5U01 AI069428NIAID NIH HHS 5U01 AI069447 03NIAID NIH HHS 5U01 AI069470NIAID NIH HHS 5U01 AI069470-03NIAID NIH HHS 5U01 AI069471NIAID NIH HHS 5U01 AI069484-02NIAID NIH HHS AI032782NIAID NIH HHS AI069424NIAID NIH HHS AI069434NIAID NIH HHS AI069439NIAID NIH HHS AI069471NIAID NIH HHS AI069472NIAID NIH HHS AI069474NIAID NIH HHS AI069477NIAID NIH HHS AI069495NIAID NIH HHS AI069501NIAID NIH HHS AI069513NIAID NIH HHS AI069532NIAID NIH HHS AI073961NIAID NIH HHS AI25868NIAID NIH HHS AI27661NIAID NIH HHS AI27666NIAID NIH HHS AI27675NIAID NIH HHS AI34853NIAID NIH HHS AI38858NIAID NIH HHS AI46370NIAID NIH HHS AI50410NIAID NIH HHS AI58740NIAID NIH HHS AI68634NIAID NIH HHS AI69419NIAID NIH HHS AI69423NIAID NIH HHS AI69432NIAID NIH HHS AI69465NIAID NIH HHS AI69501NIAID NIH HHS AI69556NIAID NIH HHS N01 AI72626NIAID NIH HHS P30 AI045008NIAID NIH HHS P30 AI050409NIAID NIH HHS P30 AI050410NIAID NIH HHS P30 AI073961NIAID NIH HHS R01 AI058740NIAID NIH HHS U01 AI025859NIAID NIH HHS U01 AI025868NIAID NIH HHS U01 AI027661NIAID NIH HHS U01 AI027666NIAID NIH HHS U01 AI027675NIAID NIH HHS U01 AI032782NIAID NIH HHS U01 AI034853NIAID NIH HHS U01 AI038858NIAID NIH HHS U01 AI046370NIAID NIH HHS U01 AI046376NIAID NIH HHS U01 AI068634NIAID NIH HHS U01 AI068636NIAID NIH HHS U01AI068636NIAID NIH HHS U01 AI069415NIAID NIH HHS U01 AI069418NIAID NIH HHS U01 AI069419NIAID NIH HHS U01 AI069423NIAID NIH HHS U01 AI069424NIAID NIH HHS U01 AI069428NIAID NIH HHS U01 AI069432NIAID NIH HHS U01 AI069434NIAID NIH HHS U01 AI069439NIAID NIH HHS U01 AI069447NIAID NIH HHS U01 AI069452NIAID NIH HHS U01 AI069452-03NIAID NIH HHS U01 AI069465NIAID NIH HHS U01 AI069467NIAID NIH HHS U01 AI069467-03NIAID NIH HHS U01 AI069470NIAID NIH HHS U01 AI069471NIAID NIH HHS U01 AI069472NIAID NIH HHS U01 AI069474NIAID NIH HHS U01 AI069477NIAID NIH HHS U01 AI069484NIAID NIH HHS U01 AI069494NIAID NIH HHS U01 AI069495NIAID NIH HHS U01 AI069501NIAID NIH HHS U01 AI069502NIAID NIH HHS U01 AI069511NIAID NIH HHS U01 AI069513NIAID NIH HHS U01 AI069532NIAID NIH HHS U01 AI069556NIAID NIH HHS UM1 AI068634NIAID NIH HHS UM1 AI069415NIAID NIH HHS UM1 AI069419NIAID NIH HHS UM1 AI069423NIAID NIH HHS UM1 AI069424NIAID NIH HHS UM1 AI069432NIAID NIH HHS UM1 AI069434NIAID NIH HHS UM1 AI069439NIAID NIH HHS UM1 AI069465NIAID NIH HHS UM1 AI069471NIAID NIH HHS UM1 AI069472NIAID NIH HHS UM1 AI069474NIAID NIH HHS UM1 AI069477NIAID NIH HHS UM1 AI069495NIAID NIH HHS UM1 AI069501NIAID NIH HHS UM1 AI069513NIAID NIH HHS UM1 AI069532NIAID NIH HHS UM1 AI069556PHS HHS 1U01 A1069423-01PHS HHS 5U01 A1027658PHS HHS U0I A106947203
6 · The paper itself

Abstract

backgroundAIDS Clinical Trials Group A5202 compared blinded abacavir/lamivudine (ABC/3TC) to tenofovir DF/emtricitabine (TDF/FTC) with efavirenz (EFV) or atazanavir/ritonavir (ATV/r) in human immunodeficiency virus (HIV)-infected treatment-naive patients, stratified by screening HIV RNA (< or ≥ 10(5) copies/mL). Due to higher virologic failure with ABC/3TC in the high HIV RNA stratum, blinded treatment was stopped in this group, but study follow-up continued for all patients.

methodsPrimary endpoints were times to virologic failure, regimen modification, and safety event.

resultsIn the low HIV RNA stratum, time to virologic failure was similar for ABC/3TC vs TDF/FTC with ATV/r (hazard ratio [HR] 1.25, 95% confidence interval [CI] 0.76, 2.05) or EFV (HR 1.23, 95% CI 0.77, 1.96), with significantly shorter times to regimen modification for ABC/3TC with EFV or ATV/r and to safety events with EFV. Prior to stopping blinded treatment in the high stratum, higher virologic failure rates were seen with ABC/3TC with EFV (HR 2.46, 95% CI 1.20, 5.05) or ATV/r (HR 2.22, 95% CI 1.19, 4.14).

conclusionsIn the low HIV RNA stratum, times to virologic failure for ABC/3TC or TDF/FTC were not different with EFV or ATV/r. In the high stratum, virologic failure rate was significantly higher for ABC/3TC than for TDF/FTC when given with either EFV or ATV/r.

Indexed as

AbacavirAdenineAdultAnti-HIV AgentsAntiretroviral Therapy, Highly ActiveCD4 Lymphocyte CountDeoxycytidineDideoxynucleosidesDouble-Blind MethodEmtricitabineFemaleHIVHIV InfectionsHumansKaplan-Meier EstimateLamivudineAbacavirAdenineAnti-HIV AgentsDeoxycytidineDideoxynucleosidesEmtricitabineLamivudineOrganophosphonatesRNA, ViralTenofovir

Identifiers

PMID21917892
PMCPMC3173503
OpenAlexW2143930204

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.